BDC-4182 Phase 1/2 Signal Vs. Existential Cash Cliff: Gastric Immunotherapy's Make-or-Break Q3 2026

Bolt Biotherapeutics Reports BDC-4182 Phase 1/2 Progress and Q2 2026 Financials

Bolt Biotherapeutics announced its financial results for the second quarter ended June 30, 2026, alongside a business update. The company reported a cash balance of $18.1 million, which is anticipated to fund operations into the first quarter of 2027. Progress continues in the Phase 1/2 study of BDC-4182 for gastric and gastroesophageal cancer, with patients currently being treated in Cohort 4. The drug has been well tolerated and is showing activity consistent with its immune-stimulating mechanism. Initial clinical data from this study is expected to be released with the company's third quarter 2026 results.

• The Phase 1/2 study for BDC-4182, targeting gastric and gastroesophageal cancer, is actively progressing, with patients now being treated in Cohort 4 at a 4.0 mg/kg dose level. The company noted that BDC-4182 has demonstrated good tolerability and activity consistent with its immune-stimulating mechanism. Initial clinical data from this ongoing study is a key anticipated milestone, expected to be reported alongside the third quarter 2026 financial results.
• Bolt Biotherapeutics reported a solid financial position with cash, cash equivalents, and marketable securities totaling $18.1 million as of June 30, 2026. This capital is projected to provide a runway for funding the company's operations and key milestones into the first quarter of 2027, ensuring continued development of its lead programs.
• BDC-4182 is a next-generation Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) specifically designed to target claudin 18.2, a clinically validated marker found in various cancers. Preclinical studies have shown that BDC-4182 exhibits significant anti-tumor activity, induces immunological memory, and outperforms conventional cytotoxic ADCs, even in tumor models with low claudin 18.2 expression.

Claudin 18.2: An Emerging Target in Gastric Cancer

Claudin 18.2 (CLDN18.2) has emerged as one of the most clinically significant novel targets in gastric and gastroesophageal cancer, with overexpression observed in 50–80% of gastric cancers. Alongside CLDN18.2, a broader pipeline of molecular targets and innovative therapeutic modalities is actively reshaping the treatment landscape for these malignancies.

• CLDN18.2 / Zolbetuximab: Zolbetuximab, a first-in-class chimeric IgG1 monoclonal antibody, has been approved in Japan and exerts antitumor activity via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). It is now established as a first-line option, with ongoing trials evaluating its role in later-line settings. Additional CLDN18.2-directed modalities in development include antibody-drug conjugates (ADCs), bispecific antibodies, and CAR-T cell therapies.

• FGFR2b / Bemarituzumab: FGFR2 amplification — the most prevalent FGFR2 gene aberration in gastroesophageal cancer and disproportionately associated with diffuse-type gastric cancer and poor prognosis — has made the FGFR2 pathway an attractive therapeutic axis. Bemarituzumab, a selective anti-FGFR2b monoclonal antibody, is currently under investigation in a first-line phase III randomized trial, with FGFR2b protein overexpression being evaluated as a companion biomarker.

• TROP2: Trophoblast cell surface antigen 2 (TROP2) has been identified as a promising molecular target. Preclinical work has demonstrated that bispecific Trop2/PD-L1 third-generation CAR-T cells exhibit superior cytotoxic activity relative to monospecific constructs, with significant tumor growth reduction observed in xenograft models.

• HER2-Directed ADCs: For HER2-positive, previously treated advanced gastric cancer, trastuzumab deruxtecan (T-DXd) has emerged as the first molecularly targeted therapy to demonstrate efficacy in this refractory setting, establishing ADCs as a validated therapeutic class in this indication.

• Additional Emerging Targets: Several other molecular targets are under active investigation, including KRAS, MET, DKK1, and cytoplasmic activation/proliferation-associated protein 1 (CAPRIN-1), with research focused on enabling biomarker-driven, personalized treatment strategies across distinct patient subpopulations.

BDC-4182 Phase 1/2: Design and Anticipated Data

BDC-4182 is not the subject of the retrieved literature; however, the following trials represent key study designs and endpoints shaping the perioperative and advanced-line treatment landscape for gastric and gastroesophageal junction (GEJ) adenocarcinoma — providing relevant contextual benchmarks for emerging agents in this space.

Addressing Unmet Needs in Gastric and Gastroesophageal Cancer

Gastric and gastroesophageal cancers present a complex therapeutic landscape where multiple biological, technical, and clinical factors continue to limit treatment efficacy. Despite meaningful advances in targeted therapy and immunotherapy, durable responses remain elusive for a significant proportion of patients due to intersecting mechanisms of resistance, biomarker variability, and inconsistent treatment benefit across disease settings.

• Acquired resistance to HER2-targeted therapy: Although trastuzumab and trastuzumab deruxtecan (T-DXd) have improved outcomes in HER2-positive gastric cancer, resistance is common and mechanistically diverse. Approximately one-third of trastuzumab-resistant patients develop epithelial-mesenchymal transition (EMT), associated with upregulation of PD-L1 and CCL2, while another third activate the endoplasmic reticulum-associated degradation (ERAD) pathway via genes such as GOLM1. T-DXd-resistant tumors exhibit distinct alterations including HLA loss and increased oxidative phosphorylation pathway activity.

• Intratumoral HER2 heterogeneity: HER2/ERBB2 expression is spatially and temporally variable within individual gastric tumors, complicating patient selection for targeted therapies including T-DXd. HER2-heterogeneous tumors also harbour divergent driver and passenger mutations between HER2-positive and HER2-negative regions, further undermining predictive biomarker reliability.

• Chemotherapy toxicity and resistance: Anthracycline-based triplet regimens have been largely abandoned due to unfavourable toxicity profiles without superior efficacy. Comparative data demonstrate that modified DCF is associated with significantly higher rates of haematologic and gastrointestinal complications, creatinine elevation, stomatitis, and alopecia versus FOLFOX. In aggressive presentations such as skin metastases from gastroesophageal junction adenocarcinoma, sequential first-, second-, and third-line regimens — including FOLFOX, FOLFIRI, and taxanes — have each failed to arrest disease progression.

• Biomarker assessment inconsistencies: PD-L1 combined positive score (CPS) evaluation is limited by poor interobserver concordance among pathologists, despite its growing role in guiding clinical treatment decisions. Similarly, CLDN18.2 positivity (≥75% cutoff) shows only 73% concordance between matched primary and metastatic samples and 74% concordance across pre- and post-chemotherapy specimens, reflecting meaningful variability in expression across disease sites and treatment exposure.

• Heterogeneous treatment response and limited predictive tools: Amplifications of key driver genes — including MET, EGFR, and FGFR2 — detected in circulating tumour DNA are associated with numerically lower objective response rates to T-DXd, underscoring the need for robust, validated predictive biomarkers. Response heterogeneity across patients highlights the current inadequacy of tools available to guide personalised treatment selection.

• Lack of benefit from targeted agents in specific clinical settings: In resected stage III gastric cancer, the addition of nivolumab to adjuvant chemotherapy failed to improve 3-year disease-free survival over chemotherapy alone. Similarly, the addition of trastuzumab to chemoradiotherapy and surgery in HER2-positive locally advanced esophageal and gastroesophageal junction adenocarcinoma did not yield an overall survival benefit compared to chemoradiotherapy and surgery without trastuzumab.